The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...

“With low uptake of PrEP among the communities most impacted by HIV, this insurance coverage requirement with zero ...

Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a prescription drug that’s used to treat HIV. This drug can interact with other medications and some ...

Biktarvy is the number one prescribed regimen ... approved for the treatment of HIV-1 infection and PrEP. The strong results increase the probability of lenacapavir’s approval that should ...

The rates of HIV suppression at Week 48 in the combination and Biktarvy arms were 94.2% and 92.3%, respectively. The figures for both cohorts were 94.2% at Week 24. The potential advantage over ...

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...

Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...

Biktarvy is Gilead’s once-a-day single tablet, which is used to treat HIV-1 in adults and children. These patients were randomly allocated in two arms equally to receive either oral islatravir 2 ...